The ability to conduct multiple experiments in parallel significantly reduces the time that it takes to develop a manufacturing process for a biopharmaceutical. This is particularly significant before clinical entry, because process development and manufacturing are on the “critical path” for a drug candidate to enter clinical development. High-throughput process development (HTPD) methodologies can be similarly impactful during late-stage development, both for developing the final commercial process as well as for process characterization and scale-down validation activities that form a key component of the licensure filing package. This review examines the current state of the art for HTPD methodologies as they apply to cell culture, downstream purification, and analytical techniques. In addition, we provide a vision of how HTPD activities across all of these spaces can integrate to create a rapid process development engine that can accelerate biopharmaceutical drug development.
CITATION STYLE
Shukla, A. A., Rameez, S., Wolfe, L. S., & Oien, N. (2018). High-throughput process development for biopharmaceuticals. In Advances in Biochemical Engineering/Biotechnology (Vol. 165, pp. 401–441). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/10_2017_20
Mendeley helps you to discover research relevant for your work.